HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Noncytotoxic drug therapy for intra-abdominal desmoid tumor in patients with familial adenomatous polyposis.

Abstract
Forty of 416 patients with familial adenomatous polyposis were noted to have intra-abdominal desmoid tumors, and a subgroup of 16 were treated with noncytotoxic drug therapy. Drugs used were sulindac (14 patients), sulindac plus tamoxifen (3 patients), indomethacin (4 patients), tamoxifen (4 patients), progesterone (DEPO-PROVERA; Upjohn Co., Kalamazoo, MI) (2 patients), and testolactone (1 patient). Therapy with these drugs for continuous periods of six months or more resulted in three complete and seven partial remissions. When treated patients were compared with untreated patients (n = 12), there were significant benefits for the treated group, both in reduction of desmoid size and in improvement of symptoms, despite the inherent selection bias against this. Sulindac was the only drug used in enough patients to permit independent evaluation of its effect, with one complete and seven partial reductions of tumor size. Some patients had a delayed response to sulindac, with tumor shrinkage occurring after an initial period of tumor enlargement. When using sulindac for the treatment of desmoid tumors, this phenomenon should be considered.
AuthorsK Tsukada, J M Church, D G Jagelman, V W Fazio, E McGannon, C R George, T Schroeder, I Lavery, J Oakley
JournalDiseases of the colon and rectum (Dis Colon Rectum) Vol. 35 Issue 1 Pg. 29-33 (Jan 1992) ISSN: 0012-3706 [Print] United States
PMID1310270 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Sulindac
Topics
  • Abdominal Neoplasms (drug therapy, pathology, physiopathology)
  • Adenomatous Polyposis Coli
  • Adult
  • Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
  • Female
  • Fibroma (drug therapy, pathology, physiopathology)
  • Humans
  • Male
  • Neoplasms, Multiple Primary (drug therapy)
  • Pain (etiology, prevention & control)
  • Remission Induction
  • Retrospective Studies
  • Sulindac (administration & dosage, adverse effects)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: